Treatment Choice

DRUG3 trials

Sponsors

Astex Pharmaceuticals, Inc.

Conditions

Leukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMyelodysplastic Syndromesblood- and bone marrow cancer

Phase 3

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

CompletedNCT02348489

Astex Pharmaceuticals, Inc.Leukemia, Myeloid, Acute

Start: 2015-03-19End: 2019-06-17Updated: 2024-08-27

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

CompletedNCT02907359

Astex Pharmaceuticals, Inc.Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes

Start: 2017-01-13End: 2020-11-30Updated: 2024-08-27

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Active, not recruitingNL-OMON45193

Astex Pharmaceuticals, Inc.blood- and bone marrow cancer

Start: 2016-04-07Target: 10Updated: 2024-02-28

Related Papers

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

HemaSphere2023-08-011 citations

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Blood Advances2023-06-0520 citations

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood2018-11-295 citations

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

2017-08-24115 citations

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Blood2015-12-038 citations